A 24-week prospective, multicenter, real-world study on eptinezumab’s effectiveness and safety in migraine prevention (EMBRACE II) — Piero Barbanti (2025) | RDL Network
A 24-week prospective, multicenter, real-world study on eptinezumab’s effectiveness and safety in migraine prevention (EMBRACE II)
Article 2025 en
Authors
PB
Piero Barbanti
CA
Cinzia Aurilia
GE
Gabriella Egeo
Abstract
1 min read
This real-world study documents that 24-week eptinezumab treatment is rapidly effective and well tolerated in migraine patients with multiple therapeutic failures (including anti-CGRP mAbs). One-third of patients escalated to 300 mg at week 12, achieving further significant migraine-related disability reduction.
Discussion(0)
No comments yet. Be the first to comment.